CoChat
Sign Up
Cited by 381

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer

Gustavsson, Bengt, Carlsson, Göran, Machover, David, Petrelli, Nicholas, Roth, Arnaud, Schmoll, Hans-Joachim, Tveit, Kjell-Magne, Gibson, Fernando·2015·Clinical Colorectal Cancer
DOI 10.1016/j.clcc.2014.11.002
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clcc.2014.11.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 82

  1. Lombardi, 2010, Adjuvant colon cancer chemotherapy: where we are and where we'll go, Cancer Treat Rev, 36, S34, 10.1016/S0305-7372(10)70018-9 · DOI
  2. Engstrom, 2009, NCCN clinical practice guidelines in oncology: colon cancer, J Natl Compr Canc Netw, 7, 778, 10.6004/jnccn.2009.0056 · DOI
  3. Wilkinson, 2010, Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials, Ann Surg Oncol, 17, 959, 10.1245/s10434-009-0881-y · DOI
  4. Gill, 2007, Colorectal cancer, Mayo Clin Proc, 82, 114, 10.1016/S0025-6196(11)60974-9 · DOI
  5. Scheithauer, 1993, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer, BMJ, 306, 752, 10.1136/bmj.306.6880.752 · DOI · Paper page
  6. Lucas, 2011, A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer, Clin Colorectal Cancer, 10, 238
  7. DeVita, 2008, A history of cancer chemotherapy, Cancer Res, 68, 8643, 10.1158/0008-5472.CAN-07-6611 · DOI
  8. Heidelberger, 1957, Fluorinated pyrimidines, a new class of tumour-inhibitory compounds, Nature, 179, 663, 10.1038/179663a0 · DOI · Paper page
  9. Danenberg, 1977, Thymidylate synthetase - a target enzyme in cancer chemotherapy, Biochim Biophys Acta, 473, 73
  10. Hartmann, 1961, Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase, J Biol Chem, 236, 3006, 10.1016/S0021-9258(19)76419-9 · DOI
  11. Houghton, 1981, Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice, Cancer Res, 41, 144
  12. Santi, 1974, Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate, Biochemistry, 13, 471, 10.1021/bi00700a012 · DOI
  13. Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, 92, 414, 10.1038/clpt.2012.96 · DOI
  14. Spears, 1984, Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil, Cancer Res, 44, 4144
  15. Peters, 1989, In vitro and in vivo inhibition of thymidylate synthase of human colon cancer by 5-fluorouracil, Adv Exp Med Biol, 253A, 439, 10.1007/978-1-4684-5673-8_72 · DOI
  16. Friedkin, 1973, Thymidylate synthetase, Adv Enzymol Relat Areas Mol Biol, 38, 235
  17. Huennekens, 1987, Folic acid metabolism and its disruption by pharmacologic agents, NCI Monogr, 1
  18. Ullman, 1978, Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate, Proc Natl Acad Sci U S A, 75, 980, 10.1073/pnas.75.2.980 · DOI
  19. Keyomarsi, 1986, Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells, Cancer Res, 46, 5229
  20. Rustum, 1987, Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin, NCI Monogr, 165
  21. Evans, 1981, Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil, Cancer Res, 41, 3288
  22. Farber, 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid, N Engl J Med, 238, 787, 10.1056/NEJM194806032382301 · DOI
  23. van der Wilt, 1993, Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase, Biochem Pharmacol, 45, 1177, 10.1016/0006-2952(93)90267-Z · DOI
  24. Radparvar, 1989, Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft, Biochem Pharmacol, 38, 335, 10.1016/0006-2952(89)90046-4 · DOI
  25. Allegra, 1985, Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates, J Biol Chem, 260, 9720, 10.1016/S0021-9258(17)39298-0 · DOI
  26. Waxman, 1982, The enhancement of 5-fluorouracil anti-metabolic activity by leucovorin, menadione and alpha-tocopherol, Eur J Cancer Clin Oncol, 18, 685, 10.1016/0277-5379(82)90215-2 · DOI
  27. Mini, 1987, Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells, Biochem Pharmacol, 36, 2905, 10.1016/0006-2952(87)90201-2 · DOI
  28. Mini, 1987, Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin, Cancer Treat Rep, 71, 381
  29. Park, 1988, Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines, J Natl Cancer Inst, 80, 1560, 10.1093/jnci/80.19.1560 · DOI
  30. Chang, 1989, Enhancement of fluoropyrimidine inhibition of cell growth by leucovorin and deoxynucleosides in a human squamous cell carcinoma cell line, Cancer Invest, 7, 557, 10.3109/07357908909017530 · DOI
  31. Mini, 1990, Enhancement of the antitumor effects of 5-fluorouracil by folinic acid, Pharmacol Ther, 47, 1, 10.1016/0163-7258(90)90042-Z · DOI
  32. Poon, 1989, Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma, J Clin Oncol, 7, 1407, 10.1200/JCO.1989.7.10.1407 · DOI
  33. Machover, 1982, Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study, Cancer Treat Rep, 66, 1803
  34. Madajewicz, 1984, Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer, Cancer Res, 44, 4667
  35. Petrelli, 1987, A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma, J Clin Oncol, 5, 1559, 10.1200/JCO.1987.5.10.1559 · DOI
  36. Petrelli, 1989, The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group, J Clin Oncol, 7, 1419, 10.1200/JCO.1989.7.10.1419 · DOI
  37. Thirion, 2004, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis, J Clin Oncol, 22, 3766, 10.1200/JCO.2004.03.104 · DOI
  38. Kunimoto, 1987, Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors, Cancer Res, 47, 5944
  39. Illum, 2011, Irinotecan and radiosensitization in rectal cancer, Anticancer Drugs, 22, 324, 10.1097/CAD.0b013e3283425c14 · DOI
  40. Kidani, 1980, Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers, Gan, 71, 637
  41. Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302 · DOI
  42. Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 · DOI
  43. Colucci, 2005, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale, J Clin Oncol, 23, 4866, 10.1200/JCO.2005.07.113 · DOI
  44. Souglakos, 2006, Br J Cancer, 94, 798, 10.1038/sj.bjc.6603011 · DOI
  45. Falcone, 2007, J Clin Oncol, 25, 1670, 10.1200/JCO.2006.09.0928 · DOI · Paper page
  46. Folkman, 1971, Isolation of a tumor factor responsible for angiogenesis, J Exp Med, 133, 275, 10.1084/jem.133.2.275 · DOI · Paper page
  47. Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 · DOI · Paper page
  48. Kawamoto, 1983, Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody, Proc Natl Acad Sci U S A, 80, 1337, 10.1073/pnas.80.5.1337 · DOI
  49. Masui, 1984, Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies, Cancer Res, 44, 1002
  50. Sato, 1983, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors, Mol Biol Med, 1, 511
  51. Gill, 1984, Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity, J Biol Chem, 259, 7755, 10.1016/S0021-9258(17)42857-2 · DOI
  52. Lievre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 66, 3992, 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
  53. Van Cutsem, 2011, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, 29, 2011, 10.1200/JCO.2010.33.5091 · DOI · Paper page
  54. Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 · DOI
  55. Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 · DOI · Paper page
  56. Tveit, 2012, Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study, J Clin Oncol, 30, 1755, 10.1200/JCO.2011.38.0915 · DOI
  57. Heinemann, 2013, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, J Clin Oncol, 31
  58. Falcone, 2013, FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group (abstract 3505), J Clin Oncol, 31
  59. Schwartzberg, 2013, Analysis of KRAS/NRAS mutations in PEAK: a randomized study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) (abstract 3631), J Clin Oncol, 31
  60. Schwartzberg, 2012, PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC) (abstract 446), J Clin Oncol, 30
  61. Bin, 2011, Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials, Colorectal Dis, 13, 837, 10.1111/j.1463-1318.2009.02184.x · DOI
  62. Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676 · DOI
  63. Janssen, 1976, The levamisole story, Prog Drug Res, 20, 347
  64. Renoux, 1980, The general immunopharmacology of levamisole, Drugs, 20, 89, 10.2165/00003495-198020020-00001 · DOI
  65. Laurie, 1989, Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic, J Clin Oncol, 7, 1447, 10.1200/JCO.1989.7.10.1447 · DOI
  66. Moertel, 1990, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 322, 352, 10.1056/NEJM199002083220602 · DOI
  67. Cassidy, 1994, Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?, Br J Cancer, 69, 986, 10.1038/bjc.1994.193 · DOI
  68. Wolmark, 1993, The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03, J Clin Oncol, 11, 1879, 10.1200/JCO.1993.11.10.1879 · DOI
  69. 1995, Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, Lancet, 345, 939, 10.1016/S0140-6736(95)90696-7 · DOI
  70. Haller, 2005, Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089, J Clin Oncol, 23, 8671, 10.1200/JCO.2004.00.5686 · DOI
  71. Saini, 2003, Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer, Br J Cancer, 88, 1859, 10.1038/sj.bjc.6600995 · DOI
  72. Andre, 2007, Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1, J Clin Oncol, 25, 3732, 10.1200/JCO.2007.12.2234 · DOI
  73. de Gramont, 1997, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study, J Clin Oncol, 15, 808, 10.1200/JCO.1997.15.2.808 · DOI
  74. Twelves, 2005, Capecitabine as adjuvant treatment for stage III colon cancer, N Engl J Med, 352, 2696, 10.1056/NEJMoa043116 · DOI
  75. Lembersky, 2006, Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06, J Clin Oncol, 24, 2059, 10.1200/JCO.2005.04.7498 · DOI
  76. Andre, 2004, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, 2343, 10.1056/NEJMoa032709 · DOI
  77. Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, 27, 3109, 10.1200/JCO.2008.20.6771 · DOI
  78. Van Cutsem, 2009, Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3, J Clin Oncol, 27, 3117, 10.1200/JCO.2008.21.6663 · DOI
  79. Saltz, 2007, Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J Clin Oncol, 25, 3456, 10.1200/JCO.2007.11.2144 · DOI
  80. Ychou, 2009, A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802), Ann Oncol, 20, 674, 10.1093/annonc/mdn680 · DOI
  81. Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 29, 11, 10.1200/JCO.2010.30.0855 · DOI
  82. Alberts, 2012, Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, 307, 1383, 10.1001/jama.2012.385 · DOI

Cited by

Sorted by citations

See all 381

Metadata

Authors
Gustavsson, B., Carlsson, G., Machover, D., Petrelli, N., Roth, A., Schmoll, H.-J., Tveit, K.-M., & Gibson, F.
Venue
Clinical Colorectal Cancer
Publisher
Elsevier BV
Published
2015-03
Volume
14
Issue
1
Pages
1-10
ISSN
1533-0028
DOI
10.1016/j.clcc.2014.11.002
Cited by
381
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review